Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023
Alkermes plc (Nasdaq: ALKS) will conduct a conference call and webcast on February 16, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will conduct a conference call and webcast on February 16, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results. The management will also outline financial expectations for 2023 and provide company updates. Interested parties can access the webcast through Alkermes' website. U.S. callers can join by dialing +1 877 407 2988, while international callers can reach +1 201 389 0923. A replay will be available two hours post-event.
Positive
- The upcoming conference call allows investors to gain insights into financial performance and future expectations.
Negative
- No financial results or specific guidance for 2023 are provided in advance, potentially causing uncertainty among investors.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -0.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-feb-16-2023-301743184.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.